{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:58:11Z","timestamp":1767851891174,"version":"3.49.0"},"reference-count":221,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Methods"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ymeth.2021.04.026","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T22:53:49Z","timestamp":1620168829000},"page":"29-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Therapeutic approaches for SARS-CoV-2 infection"],"prefix":"10.1016","volume":"195","author":[{"given":"Ankur","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vimal K.","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swatantra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angila","family":"Theengh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailendra K.","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10273","key":"10.1016\/j.ymeth.2021.04.026_b0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0140-6736(21)00298-1","article-title":"Understanding variants of SARS-CoV-2","volume":"397","author":"Burki","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymeth.2021.04.026_b0010","article-title":"Immune modulation in COVID-19: strategic considerations for personalized therapeutic intervention","author":"Hall","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ymeth.2021.04.026_b0015","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3389\/fimmu.2020.01841","article-title":"Mechanisms underlying potential therapeutic approaches for COVID-19","volume":"11","author":"Benani","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2020.138277","article-title":"COVID-19: a promising cure for the global panic","volume":"725","author":"Vellingiri","year":"2020","journal-title":"Sci. Total Environ."},{"issue":"8","key":"10.1016\/j.ymeth.2021.04.026_b0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-020-0732-3","article-title":"Immune-mediated approaches against COVID-19","volume":"15","author":"Florindo","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11010-020-03935-z","article-title":"SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions","volume":"476","author":"Asrani","year":"2021","journal-title":"Mol. Cell Biochem."},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0035","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/v12101092","article-title":"Potential anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: a comprehensive review","volume":"12","author":"Al-Horani","year":"2020","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0040","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","article-title":"The Architecture of SARS-CoV-2 transcriptome","volume":"181","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymeth.2021.04.026_b0045","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9492","article-title":"Identification of novel mutations in RNA-dependent RNA polymerases of SARS-CoV-2 and their implications on its protein structure","volume":"8","author":"Chand","year":"2020","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cell.2020.06.034","article-title":"The global phosphorylation landscape of SARS-CoV-2 infection","volume":"182","author":"Bouhaddou","year":"2020","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ymeth.2021.04.026_b0055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S2213-8587(20)30220-5","article-title":"Metabolic health and COVID-19: a call for greater medical nutrition education","volume":"8","author":"Burridge","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0060","doi-asserted-by":"crossref","unstructured":"R. Silverio, D.C. Gon\u00e7alves, M.F. Andrade, M. Seelaender, Coronavirus Disease 2019 (COVID-19) and nutritional status: the missing link? Adv. Nutr. (2020) nmaa125. Advance online publication. 10.1093\/advances\/nmaa125.","DOI":"10.1093\/advances\/nmaa125"},{"key":"10.1016\/j.ymeth.2021.04.026_b0065","doi-asserted-by":"crossref","DOI":"10.1002\/lim2.2","article-title":"Metabolic health and lifestyle medicine should be a cornerstone of future pandemic preparedness","volume":"1","author":"Wood","year":"2020","journal-title":"Lifestyle Med."},{"issue":"19","key":"10.1016\/j.ymeth.2021.04.026_b0070","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.3390\/ijms21197090","article-title":"Role of SARS-CoV-2 in altering the RNA-binding protein and miRNA-directed post-transcriptional regulatory networks in humans","volume":"21","author":"Srivastava","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.ymeth.2021.04.026_b0075","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The Incubation Period of Coronavirus Disease 2019 (COVID-19) From publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.ymeth.2021.04.026_b0085","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/anae.15093","article-title":"Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review","volume":"75","author":"Wilson","year":"2020","journal-title":"Anaesthesia"},{"issue":"10224","key":"10.1016\/j.ymeth.2021.04.026_b0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"6491","key":"10.1016\/j.ymeth.2021.04.026_b0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol J."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ymeth.2021.04.026_b0110","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.apsb.2020.04.009","article-title":"Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites","volume":"10","author":"Kang","year":"2020","journal-title":"Acta Pharm. Sin B."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000054","article-title":"SARS-coronavirus replication\/transcription complexes are membrane-protected and need a host factor for activity in vitro","volume":"4","author":"van Hemert","year":"2008","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.ymeth.2021.04.026_b0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/13543776.2020.1760838","article-title":"A deadly spillover: SARS-CoV-2 outbreak","volume":"30","author":"Mori","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0125","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40121-020-00328-z","article-title":"Correction to: a systematic review of the clinical utility of cycle threshold values in the context of COVID-19","volume":"9","author":"Rao","year":"2020","journal-title":"Infect. Dis. Ther."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/thoraxjnl-2020-215042","article-title":"Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection","volume":"76","author":"Ra","year":"2021","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.ymeth.2021.04.026_b0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41574-020-0364-6","article-title":"Obesity and impaired metabolic health in patients with COVID-19","volume":"16","author":"Stefan","year":"2020","journal-title":"Nat Rev Endocrinol."},{"issue":"9","key":"10.1016\/j.ymeth.2021.04.026_b0140","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-8587(20)30238-2","article-title":"COVID-19 in people with diabetes: understanding the reasons for worse outcomes","volume":"8","author":"Apicella","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.ymeth.2021.04.026_b0145","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s10067-020-05234-w","article-title":"A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab","volume":"39","author":"Cai","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0150","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14096","article-title":"Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic","volume":"33","author":"Kutlu","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ymeth.2021.04.026_b0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40734-020-00089-4","article-title":"Potential impact and challenges associated with Parkinson\u2019s disease patient care amidst the COVID-19 global pandemic","volume":"7","author":"Elbeddini","year":"2020","journal-title":"J. Clin. Mov. Disord."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13195-020-00640-3","article-title":"Immediate and long-term consequences of COVID-19 infections for the development of neurological disease","volume":"12","author":"Heneka","year":"2020","journal-title":"Alzheimers Res. Ther."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0165","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/jce.14479","article-title":"Cardiac and arrhythmic complications in patients with COVID-19","volume":"31","author":"Kochi","year":"2020","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0170","doi-asserted-by":"crossref","first-page":"W87","DOI":"10.1097\/RTI.0000000000000534","article-title":"Long-term Pulmonary Consequences of Coronavirus Disease 2019 (COVID-19): what we know and what to expect","volume":"35","author":"Salehi","year":"2020","journal-title":"J. Thorac Imaging."},{"key":"10.1016\/j.ymeth.2021.04.026_b0175","article-title":"A Systematic Review of Asymptomatic Infections with COVID-19","author":"Gao","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0180","doi-asserted-by":"crossref","first-page":"323","DOI":"10.7326\/L20-0894","article-title":"Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19","volume":"173","author":"Narasaraju","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.2000513","article-title":"Inflammasomes and pyroptosis as therapeutic targets for COVID-19","volume":"205","author":"Yap","year":"2020","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.ymeth.2021.04.026_b0190","doi-asserted-by":"crossref","first-page":"e0235458","DOI":"10.1371\/journal.pone.0235458","article-title":"Clinical characteristics of 82 cases of death from COVID-19","volume":"15","author":"Zhang","year":"2020","journal-title":"PLoS ONE"},{"issue":"10223","key":"10.1016\/j.ymeth.2021.04.026_b0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China. Lancet."},{"issue":"15","key":"10.1016\/j.ymeth.2021.04.026_b0200","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"18","key":"10.1016\/j.ymeth.2021.04.026_b0210","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0215","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jinf.2020.03.019","article-title":"Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up","volume":"80","author":"Wang","year":"2020","journal-title":"J. Infect."},{"issue":"7","key":"10.1016\/j.ymeth.2021.04.026_b0220","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1515\/cclm-2020-0198","article-title":"Laboratory abnormalities in patients with COVID-2019 infection","volume":"58","author":"Lippi","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0225","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/imm.13223","article-title":"Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China","volume":"160","author":"Tan","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.ymeth.2021.04.026_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102763","article-title":"Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients","volume":"55","author":"Liu","year":"2020","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0235","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jinf.2020.02.016","article-title":"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China","volume":"80","author":"Yang","year":"2020","journal-title":"J. Infect."},{"issue":"17","key":"10.1016\/j.ymeth.2021.04.026_b0240","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMc2005073","article-title":"SARS-CoV-2 infection in children","volume":"382","author":"Lu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymeth.2021.04.026_b0245","doi-asserted-by":"crossref","first-page":"m606","DOI":"10.1136\/bmj.m606","article-title":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series","volume":"368","author":"Xu","year":"2020","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.ymeth.2021.04.026_b0250","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/cid\/ciaa199","article-title":"Clinical characteristics of imported cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: a multicenter descriptive study","volume":"71","author":"Wu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ymeth.2021.04.026_b0255","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"issue":"10223","key":"10.1016\/j.ymeth.2021.04.026_b0260","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"7798","key":"10.1016\/j.ymeth.2021.04.026_b0265","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0270","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41392-020-00296-3","article-title":"Immune characteristics of severe and critical COVID-19 patients","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.ymeth.2021.04.026_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104792","article-title":"Coronavirus membrane fusion mechanism offers a potential target for antiviral development","volume":"178","author":"Tang","year":"2020","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0280","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.tim.2004.08.008","article-title":"Cellular entry of the SARS coronavirus","volume":"12","author":"Hofmann","year":"2004","journal-title":"Trends Microbiol."},{"issue":"6485","key":"10.1016\/j.ymeth.2021.04.026_b0285","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0290","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1038\/s41598-020-70863-9","article-title":"An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors","volume":"10","author":"Trezza","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0295","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13337-020-00598-8","article-title":"Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor","volume":"31","author":"Maurya","year":"2020","journal-title":"Virusdisease."},{"key":"10.1016\/j.ymeth.2021.04.026_b0300","first-page":"1","article-title":"Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection","author":"Maurya","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0305","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"15","key":"10.1016\/j.ymeth.2021.04.026_b0310","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0315","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/15563650500514558","article-title":"Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia","volume":"44","author":"Chen","year":"2006","journal-title":"Clin Toxicol (Phila)."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0320","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1113\/expphysiol.2007.040048","article-title":"The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice","volume":"93","author":"Imai","year":"2008","journal-title":"Exp. Physiol."},{"issue":"11","key":"10.1016\/j.ymeth.2021.04.026_b0325","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450117666160727142401","article-title":"The anti-inflammatory potential of ACE2\/Angiotensin-(1\u20137)\/Mas Receptor axis: evidence from basic and clinical research","volume":"18","author":"Rodrigues Prestes","year":"2017","journal-title":"Curr. Drug Targets."},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0330","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/v12060629","article-title":"The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner","volume":"12","author":"Yamamoto","year":"2020","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.ymeth.2021.04.026_b0335","doi-asserted-by":"crossref","first-page":"e202000786","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci. Alliance"},{"issue":"11","key":"10.1016\/j.ymeth.2021.04.026_b0340","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3390\/cells9112377","article-title":"Aprotinin inhibits SARS-CoV-2 replication","volume":"9","author":"Bojkova","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0345","doi-asserted-by":"crossref","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymeth.2021.04.026_b0350","unstructured":"Camostat mesilate treating patients with hospitalized patients with COVID-19 (RECOVER). NCT04470544. NIH U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04470544 (Accessed on 10th Nov 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b0355","unstructured":"Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia. NCT04418128. NIH U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509999 (Accessed on 10th Nov 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b0360","unstructured":"Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection. NCT04509999. NIH U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509999 (Accessed on 10th Nov 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b0365","first-page":"1","article-title":"Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches","author":"Idris","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ymeth.2021.04.026_b0370","article-title":"Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies","volume":"890","author":"Pooja","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107587","article-title":"Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients","volume":"213","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"518","key":"10.1016\/j.ymeth.2021.04.026_b0380","doi-asserted-by":"crossref","first-page":"eaao0422","DOI":"10.1126\/scisignal.aao0422","article-title":"Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis","volume":"11","author":"Tripathi","year":"2018","journal-title":"Sci. Signal."},{"issue":"21","key":"10.1016\/j.ymeth.2021.04.026_b0385","doi-asserted-by":"crossref","first-page":"e01218","DOI":"10.1128\/JVI.01218-20","article-title":"Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo","volume":"94","author":"Weston","year":"2020","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.ymeth.2021.04.026_b0390","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11095-020-02851-7","article-title":"Repurposing of kinase inhibitors for treatment of COVID-19","volume":"37","author":"Weisberg","year":"2020","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0395","doi-asserted-by":"crossref","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0400","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"issue":"7","key":"10.1016\/j.ymeth.2021.04.026_b0405","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol. Immunol."},{"issue":"18","key":"10.1016\/j.ymeth.2021.04.026_b0410","doi-asserted-by":"crossref","first-page":"e106275","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0415","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/22221751.2020.1780953","article-title":"SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists","volume":"9","author":"Yuen","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0420","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/acsptsci.0c00093","article-title":"Can papain-like protease inhibitors halt SARS-CoV-2 replication?","volume":"3","author":"Maiti","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0425","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin B."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0430","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.joim.2020.02.005","article-title":"In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus","volume":"18","author":"Zhang","year":"2020","journal-title":"J. Integr. Med."},{"key":"10.1016\/j.ymeth.2021.04.026_b0435","first-page":"1","article-title":"Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease","author":"Kandeel","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ymeth.2021.04.026_b0440","first-page":"1","article-title":"Cyanobacterial metabolites as promising drug leads against the Mpro and PLpro of SARS-CoV-2: an in silico analysis","author":"Naidoo","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ymeth.2021.04.026_b0445","first-page":"1","article-title":"Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms","author":"Quimque","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0450","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"6489","key":"10.1016\/j.ymeth.2021.04.026_b0455","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"7811","key":"10.1016\/j.ymeth.2021.04.026_b0460","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.ymeth.2021.04.026_b0465","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1016\/0006-2952(84)90083-2","article-title":"A novel biologically active seleno-organic compound\u2013I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen)","volume":"33","author":"M\u00fcller","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0470","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.freeradbiomed.2020.05.007","article-title":"Interaction kinetics of selenium-containing compounds with oxidants","volume":"155","author":"Carroll","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ymeth.2021.04.026_b0475","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2020.06.032","article-title":"Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections","volume":"156","author":"Sies","year":"2020","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0480","first-page":"L1057","article-title":"Endothelial permeability and IL-6 production during hypoxia: role of ROS in signal transduction","volume":"277","author":"Ali","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0485","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14218\/JCTH.2020.00018","article-title":"COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies","volume":"8","author":"Feng","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0490","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0891-5849(00)00490-1","article-title":"Ebselen prevents early alcohol-induced liver injury in rats","volume":"30","author":"Kono","year":"2001","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0495","first-page":"321","article-title":"The selenoorganic compound ebselen suppresses liver injury induced by Propionibacterium acnes and lipopolysaccharide in rats","volume":"7","author":"Koyanagi","year":"2001","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0500","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/14756366.2021.1873977","article-title":"Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro","volume":"36","author":"Liu","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ymeth.2021.04.026_b0505","article-title":"Discovery of Baicalin and Baicalein as Novel, Natural Product Inhibitors of SARS-CoV-2 3CL Protease","author":"Su","year":"2020","journal-title":"bioRxiv"},{"issue":"6497","key":"10.1016\/j.ymeth.2021.04.026_b0510","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ymeth.2021.04.026_b0515","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/microorganisms8081250","article-title":"Progress in developing inhibitors of SARS-CoV-2 3C-like protease","volume":"8","author":"Li","year":"2020","journal-title":"Microorganisms."},{"key":"10.1016\/j.ymeth.2021.04.026_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112702","article-title":"Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240079","article-title":"Biochemical screening for SARS-CoV-2 main protease inhibitors","volume":"15","author":"Coelho","year":"2020","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.ymeth.2021.04.026_b0530","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.str.2020.10.007","article-title":"Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals","volume":"28","author":"Kneller","year":"2020","journal-title":"Structure"},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240653","article-title":"Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease inhibitors: a molecular docking and simulation studies","volume":"15","author":"Cherrak","year":"2020","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0540","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","article-title":"Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents","volume":"47","author":"MacArthur","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0545","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201256","article-title":"Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy","volume":"40","author":"Shamsi","year":"2020","journal-title":"Biosci Rep."},{"key":"10.1016\/j.ymeth.2021.04.026_b0550","unstructured":"National Center for Biotechnology Information, \u201cPubChem Compound Summary for CID 66828839, Glecaprevir\u201d PubChem. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/66828839 (Accessed 12 Nov., 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral res."},{"key":"10.1016\/j.ymeth.2021.04.026_b0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1769731","article-title":"Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2","author":"Wang","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0565","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jgg.2020.02.001","article-title":"Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines","volume":"47","author":"Liu","year":"2020","journal-title":"J Genet Genomics."},{"key":"10.1016\/j.ymeth.2021.04.026_b0570","article-title":"Lopinavir-ritonavir is not an effective inhibitor of the main protease activity of SARS-CoV-2 in vitro","author":"Jang","year":"2020","journal-title":"bioRxiv"},{"issue":"19","key":"10.1016\/j.ymeth.2021.04.026_b0575","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymeth.2021.04.026_b0580","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijid.2020.05.085","article-title":"Lack of antiviral activity of darunavir against SARS-CoV-2","volume":"97","author":"De Meyer","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.ymeth.2021.04.026_b0585","doi-asserted-by":"crossref","first-page":"e00872","DOI":"10.1128\/AAC.00872-20","article-title":"Discovery of M protease inhibitors encoded by SARS-CoV-2","volume":"64","author":"Hung","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0590","doi-asserted-by":"crossref","first-page":"e00825","DOI":"10.1128\/AAC.00825-20","article-title":"Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production","volume":"64","author":"Fintelman-Rodrigues","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"48","key":"10.1016\/j.ymeth.2021.04.026_b0595","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023357","article-title":"First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"6498","key":"10.1016\/j.ymeth.2021.04.026_b0600","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0605","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ymeth.2021.04.026_b0610","unstructured":"NIH U.S. National Library of Medicine (Accessed on 10th Nov 2020) https:\/\/clinicaltrials.gov."},{"key":"10.1016\/j.ymeth.2021.04.026_b0615","unstructured":"NIH U.S. National Library of Medicine. https:\/\/www.covid19treatmentguidelines.nih.gov\/antiviral-therapy\/remdesivir\/ (Accessed on 10th Nov 2020)."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0620","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: a new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med. J. Armed Forces India"},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0625","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing, China)"},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0630","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/ijp.ijp_998_20","article-title":"Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients","volume":"52","author":"Prakash","year":"2020","journal-title":"Indian J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0635","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.gastro.2005.11.011","article-title":"American Gastroenterological Association medical position statement on the management of hepatitis C","volume":"130","author":"Dienstag","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.ymeth.2021.04.026_b0640","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3201\/eid2409.171709","article-title":"Systematic review and meta-analysis of postexposure prophylaxis for Crimean-Congo Hemorrhagic Fever Virus among healthcare workers","volume":"24","author":"Erg\u00f6n\u00fcl","year":"2018","journal-title":"Emerg. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0645","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"10.1016\/j.ymeth.2021.04.026_b0650","unstructured":"Lopinavir\/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment. NCT04276688. NIH U.S. National Library of Medicine https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688 (Accessed on 10th Nov 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b0655","unstructured":"The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19. NCT04347915. NIH U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04347915 (Accessed on 10th Nov 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b0660","unstructured":"TAF\/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study). NCT04405271. NIH U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405271 (Accessed on 10th Nov 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109905","article-title":"Natural RNA dependent RNA polymerase inhibitors: molecular docking studies of some biologically active alkaloids of Argemone mexicana","volume":"144","author":"Pandeya","year":"2020","journal-title":"Med. Hypotheses."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0670","doi-asserted-by":"crossref","first-page":"379","DOI":"10.33549\/physiolres.934492","article-title":"COVID-19 and the immune system","volume":"69","author":"Paces","year":"2020","journal-title":"Physiol. Res."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0675","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/nu12010236","article-title":"A review of micronutrients and the immune system-working in harmony to reduce the risk of infection","volume":"12","author":"Gombart","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.ymeth.2021.04.026_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198018","article-title":"Gut microbiota and Covid-19- possible link and implications","volume":"285","author":"Dhar","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.ymeth.2021.04.026_b0685","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.nutr.21.1.167","article-title":"Vitamin A, infection, and immune function","volume":"21","author":"Stephensen","year":"2001","journal-title":"Annu. Rev. Nutr."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0690","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1079\/PNS2002172","article-title":"Vitamin A as an anti-inflammatory agent","volume":"61","author":"Reifen","year":"2002","journal-title":"Proc. Nutr. Soc."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0695","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1093\/jn\/134.1.257S","article-title":"Carotenoid action on the immune response","volume":"134","author":"Chew","year":"2004","journal-title":"J. Nutr."},{"key":"10.1016\/j.ymeth.2021.04.026_b0700","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/B978-0-12-386960-9.00005-8","article-title":"Vitamin A and retinoic acid in the regulation of B-cell development and antibody production","volume":"86","author":"Ross","year":"2011","journal-title":"Vitam. Horm."},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0705","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/nu8060349","article-title":"Retinoic acid as a modulator of T cell immunity","volume":"8","author":"Bono","year":"2016","journal-title":"Nutrients"},{"issue":"15","key":"10.1016\/j.ymeth.2021.04.026_b0710","doi-asserted-by":"crossref","first-page":"15784","DOI":"10.18632\/aging.103888","article-title":"Revealing the targets and mechanisms of vitamin A in the treatment of COVID-19","volume":"12","author":"Li","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0715","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","article-title":"Vitamin D metabolism, mechanism of action, and clinical applications","volume":"21","author":"Bikle","year":"2014","journal-title":"Chem. Biol."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0720","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/physrev.00014.2015","article-title":"Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects","volume":"96","author":"Christakos","year":"2016","journal-title":"Physiol Rev."},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0725","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.3390\/nu7064240","article-title":"Modulation of the immune response to respiratory viruses by vitamin D","volume":"7","author":"Greiller","year":"2015","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.ymeth.2021.04.026_b0730","first-page":"510","article-title":"Vitamin D and the immune system","volume":"19","author":"Azrielant","year":"2017","journal-title":"Isr Med. Assoc. J."},{"issue":"27","key":"10.1016\/j.ymeth.2021.04.026_b0735","doi-asserted-by":"crossref","first-page":"19450","DOI":"10.1074\/jbc.M113.467670","article-title":"Vitamin D receptor inhibits nuclear factor \u03baB activation by interacting with I\u03baB kinase \u03b2 protein","volume":"288","author":"Chen","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0740","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13052-019-0634-x","article-title":"Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa- pilot study","volume":"45","author":"Olszowiec-Chlebna","year":"2019","journal-title":"Ital. J. Pediatr."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0745","article-title":"A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: implications for a potential treatment for COVID-19","volume":"30","author":"Malek","year":"2020","journal-title":"Rev Med Virol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0750","unstructured":"M.H. Shalayel, G.M. Al-Mazaideh, S.H. Aladaileh, F.K. Al-Swailmi, M.G. Al-Thiabat, Vitamin D is a potential inhibitor of COVID-19: in silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15. Pak. J. Pharm. Sci. 33 (2020) 2179-2186. 10.36721\/PJPS.2020.33.5.REG.2179-2186.1."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0755","doi-asserted-by":"crossref","first-page":"P23","DOI":"10.1530\/EJE-18-0736","article-title":"Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society","volume":"180","author":"Lips","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107001","article-title":"Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: an observational study","volume":"88","author":"Padhi","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.ymeth.2021.04.026_b0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239252","article-title":"SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels","volume":"15","author":"Kaufman","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymeth.2021.04.026_b0770","article-title":"Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data","volume":"356","author":"Martineau","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ymeth.2021.04.026_b0775","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.574029","article-title":"The long history of vitamin C: from prevention of the common cold to potential aid in the treatment of COVID-19","volume":"11","author":"Cerullo","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0780","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000090495","article-title":"Immune-enhancing role of vitamin C and zinc and effect on clinical conditions","volume":"50","author":"Wintergerst","year":"2006","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.ymeth.2021.04.026_b0785","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jgar.2020.09.025","article-title":"Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection","volume":"23","author":"Hoang","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b0790","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41590-019-0319-z","article-title":"Revisiting the old and learning the new of zinc in immunity","volume":"20","author":"Fukada","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0795","unstructured":"A.S. Prasad, A. Miale Jr, Z. Farid, H.H. Sandstead, A.R. Schulert, Clinical and experimental. Zinc metabolism in patients with the syndrome of iron deficiency anemia, hepatosplenomegaly, dwarfism, and hypogonadism. 1963. J. Lab. Clin. Med. 116 (5) (1990) 737\u2013749."},{"issue":"12","key":"10.1016\/j.ymeth.2021.04.026_b0800","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.tips.2018.10.001","article-title":"Copper and zinc dysregulation in Alzheimer\u2019s disease","volume":"39","author":"Sensi","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"33","key":"10.1016\/j.ymeth.2021.04.026_b0805","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.2174\/092986711797636126","article-title":"Insight to physiology and pathology of zinc(II) ions and their actions in breast and prostate carcinoma","volume":"18","author":"Gumulec","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b0810","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/advances\/nmz013","article-title":"The role of zinc in antiviral immunity","volume":"10","author":"Read","year":"2019","journal-title":"Adv Nutr."},{"key":"10.1016\/j.ymeth.2021.04.026_b0815","first-page":"1","article-title":"Zinc and COVID-19: basis of current clinical trials","author":"Pal","year":"2020","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.ymeth.2021.04.026_b0820","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3389\/fimmu.2020.01712","article-title":"The potential impact of zinc supplementation on COVID-19 pathogenesis","volume":"11","author":"Wessels","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0825","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clnesp.2020.06.003","article-title":"The key role of zinc in elderly immunity: a possible approach in the COVID-19 crisis","volume":"38","author":"de Almeida Brasiel","year":"2020","journal-title":"Clin. Nutr. ESPEN."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0830","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s13054-020-03085-0","article-title":"Micronutrient status of COVID-19 patients: a critical consideration","volume":"24","author":"Carr","year":"2020","journal-title":"Crit. Care."},{"key":"10.1016\/j.ymeth.2021.04.026_b0835","unstructured":"RECOVERY Collaborative Group, P. Horby, W.S. Lim, J.R. Emberson, M. Mafham, J.L. Bell, L. Linsell, N. Staplin, C. Brightling, A. Ustianowski, E. Elmahi, B. Prudon, C. Green, T. Felton, D. Chadwick, K. Rege, C. Fegan, L.C. Chappell, S.N. Faust, T. Jaki, K. Jeffery, A. Montgomery, K. Rowan, E. Juszczak, J.K. Baillie, R. Haynes, M.J. Landray, Dexamethasone in hospitalized patients with Covid-19 - preliminary report, N. Engl. J. Med. (2020) NEJMoa2021436. 10.1056\/NEJMoa2021436. Advance online publication."},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0840","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41577-020-00421-x","article-title":"After 62 years of regulating immunity, dexamethasone meets COVID-19","volume":"20","author":"Cain","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0845","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12577","article-title":"Alarmins and immunity","volume":"280","author":"Yang","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymeth.2021.04.026_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0855","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0860","doi-asserted-by":"crossref","first-page":"e01928","DOI":"10.1128\/mBio.01928-20","article-title":"Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2","volume":"11","author":"Busnadiego","year":"2020","journal-title":"mBio."},{"issue":"41","key":"10.1016\/j.ymeth.2021.04.026_b0865","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.1074\/jbc.AC120.013788","article-title":"Inhibition of SARS-CoV-2 by type I and type III interferons","volume":"295","author":"Felgenhauer","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.ymeth.2021.04.026_b0870","doi-asserted-by":"crossref","first-page":"e00985","DOI":"10.1128\/JVI.00985-20","article-title":"Type I and Type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures","volume":"94","author":"Vanderheiden","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"111","author":"Liu","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymeth.2021.04.026_b0880","unstructured":"Interleukin-6 Inhibitors. COVID-19 Treatment guidelines (nih.gov) (Accessed on 10th Nov 2020)."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0885","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0890","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0895","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/acr2.11140","article-title":"Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of Coronavirus Disease 2019","volume":"2","author":"Wampler","year":"2020","journal-title":"ACR Open Rheumatol."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0900","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/acr2.11135","article-title":"Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome","volume":"2","author":"Monteagudo","year":"2020","journal-title":"ACR Open Rheumatol."},{"issue":"7","key":"10.1016\/j.ymeth.2021.04.026_b0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19?Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun Rev."},{"issue":"12","key":"10.1016\/j.ymeth.2021.04.026_b0910","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1080\/21645515.2020.1808410","article-title":"COVID-19: benefits and risks of passive immunotherapeutics","volume":"16","author":"Gupta","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0915","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0920","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.ymeth.2021.04.026_b0925","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"568","key":"10.1016\/j.ymeth.2021.04.026_b0930","doi-asserted-by":"crossref","first-page":"eabe0948","DOI":"10.1126\/scitranslmed.abe0948","article-title":"Prospects for a safe COVID-19 vaccine","volume":"12","author":"Haynes","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymeth.2021.04.026_b0935","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ymeth.2021.04.026_b0940","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect Dis."},{"issue":"10","key":"10.1016\/j.ymeth.2021.04.026_b0945","article-title":"The race for a COVID-19 vaccine: current trials, novel technologies, and future directions","volume":"8","author":"Brown","year":"2020","journal-title":"Plast. Reconstr. Surg. Glob. Open."},{"issue":"11","key":"10.1016\/j.ymeth.2021.04.026_b0950","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.3390\/jcm9113561","article-title":"Vaccinomics and adversomics in the era of precision medicine: a review based on HBV, MMR, HPV, and COVID-19 vaccines","volume":"9","author":"Omersel","year":"2020","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.ymeth.2021.04.026_b0955","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001000","article-title":"Monitor for COVID-19 vaccine resistance evolution during clinical trials","volume":"18","author":"Kennedy","year":"2020","journal-title":"PLoS Biol."},{"issue":"1851","key":"10.1016\/j.ymeth.2021.04.026_b0960","first-page":"20162562","article-title":"Why does drug resistance readily evolve but vaccine resistance does not?","volume":"284","author":"Kennedy","year":"2017","journal-title":"Proc. Biol. Sci."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b0965","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe."},{"issue":"12","key":"10.1016\/j.ymeth.2021.04.026_b0970","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1080\/21645515.2020.1820808","article-title":"Recombinant vaccines for COVID-19","volume":"16","author":"Yadav","year":"2020","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.ymeth.2021.04.026_b0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2020.110849","article-title":"Physiological resiliency in diving mammals: insights on hypoxia protection using the Krogh principle to understand COVID-19 symptoms","volume":"253","author":"Williams","year":"2021","journal-title":"Comp. Biochem. Physiol. A Mol. Integr. Physiol."},{"issue":"6","key":"10.1016\/j.ymeth.2021.04.026_b0980","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.dsx.2020.10.021","article-title":"Statins and SARS-CoV-2 disease: current concepts and possible benefits","volume":"14","author":"Minz","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.ymeth.2021.04.026_b0985","article-title":"The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis","author":"Wang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ymeth.2021.04.026_b0990","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3389\/fimmu.2020.02056","article-title":"Immunomodulatory and antiviral activity of metformin and its potential implications in treating Coronavirus Disease 2019 and lung injury","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b0995","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jvsv.2020.05.018","article-title":"Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia","volume":"8","author":"Costanzo","year":"2020","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"issue":"1","key":"10.1016\/j.ymeth.2021.04.026_b1000","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000512007","article-title":"The impact of COVID-19 disease on platelets and coagulation","volume":"88","author":"Wool","year":"2021","journal-title":"Pathobiology"},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b1005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12026-020-09145-5","article-title":"COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy","volume":"68","author":"Perricone","year":"2020","journal-title":"Immunol. Res."},{"key":"10.1016\/j.ymeth.2021.04.026_b1010","doi-asserted-by":"crossref","unstructured":"K. Thibodeaux, M. Speyrer, A. Raza, R. Yaakov, T.E. Serena, Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J. Wound Care. 29 (Sup5a) (2020) S4\u2013S8. 10.12968\/jowc.2020.29.Sup5a.S4.","DOI":"10.12968\/jowc.2020.29.Sup5a.S4"},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b1015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12015-020-09973-w","article-title":"Mesenchymal stem cell therapy for COVID-19: present or future","volume":"16","author":"Golchin","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.ymeth.2021.04.026_b1020","unstructured":"National Center for Complementary and Integrative Health. What are complementary and integrative health approaches? NCCIH\u2019s Funding Priorities and Research Focus | NCCIH (nih.gov) (Accessed on 20th Nov 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b1025","unstructured":"AYUSH | National Health Portal of India (nhp.gov.in) (Accessed on 20th Nov 2020)."},{"issue":"7","key":"10.1016\/j.ymeth.2021.04.026_b1030","first-page":"2010","article-title":"Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection","volume":"10","author":"Huang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ymeth.2021.04.026_b1035","doi-asserted-by":"crossref","first-page":"2560645","DOI":"10.1155\/2020\/2560645","article-title":"Traditional herbal medicine candidates as complementary treatments for COVID-19: A review of their mechanisms, pros and cons","volume":"2020","author":"Nugraha","year":"2020","journal-title":"Evid. Based Complement Alternat. Med."},{"issue":"5","key":"10.1016\/j.ymeth.2021.04.026_b1040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/acm.2020.0129","article-title":"Public health approach of ayurveda and yoga for COVID-19 prophylaxis","volume":"26","author":"Tillu","year":"2020","journal-title":"J. Altern. Complement Med."},{"key":"10.1016\/j.ymeth.2021.04.026_b1045","article-title":"Immunity against COVID-19: potential role of Ayush Kwath","author":"Gautam","year":"2020","journal-title":"JJ Ayurveda Integr. Med."},{"key":"10.1016\/j.ymeth.2021.04.026_b1050","unstructured":"GUIDELINES for SIDDHA PRACTITIONERS for COVID 19. Ministry of AYUSH. siddhaGuidlines_v4a.cdr (ayush.gov.in) (Accessed on 20th Nov 2020)."},{"key":"10.1016\/j.ymeth.2021.04.026_b1055","unstructured":"GUIDELINES for HOMOEOPATHIC PRACTITIONERS for COVID 19. Ministry of AYUSH. https:\/\/www.ayush.gov.in\/docs\/homeopathy-guidelines.pdf (Accessed on 20th Nov 2020)."},{"issue":"Pt A","key":"10.1016\/j.ymeth.2021.04.026_b1060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ijbiomac.2020.09.199","article-title":"Synergistic immunomodulatory effect of complex polysaccharides from seven herbs and their major active fractions","volume":"165","author":"Deng","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ymeth.2021.04.026_b1065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jep.2015.07.016","article-title":"Insight into the molecular mechanism of a herbal injection by integrating network pharmacology and in vitro","volume":"173","author":"Ma","year":"2015","journal-title":"J. Ethnopharmacol."},{"issue":"3","key":"10.1016\/j.ymeth.2021.04.026_b1070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/v10030122","article-title":"Together forever: bacterial-viral interactions in infection and immunity","volume":"10","author":"Shi","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ymeth.2021.04.026_b1075","article-title":"Bacteriophages could be a potential game changer in the trajectory of coronavirus disease (COVID-19)","volume":"60\u201365","author":"Wojewodzic","year":"2020","journal-title":"Phage: Therapy Appl. Res."},{"issue":"12","key":"10.1016\/j.ymeth.2021.04.026_b1080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrrheum.2017.172","article-title":"The brain and immune system prompt energy shortage in chronic inflammation and ageing","volume":"13","author":"Straub","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymeth.2021.04.026_b1085","first-page":"30","article-title":"Phylogeny of fever","volume":"38","author":"Kluger","year":"1979","journal-title":"Fed Proc."},{"issue":"4","key":"10.1016\/j.ymeth.2021.04.026_b1090","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1189\/jlb.0108024","article-title":"Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival","volume":"84","author":"Maciver","year":"2008","journal-title":"J. Leukoc Biol."},{"key":"10.1016\/j.ymeth.2021.04.026_b1095","first-page":"1","article-title":"Photobiomodulation therapy as a high potential treatment modality for COVID-19","author":"Soheilifar","year":"2020","journal-title":"Lasers Med Sci."},{"key":"10.1016\/j.ymeth.2021.04.026_b1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotobiol.2020.112083","article-title":"The bioenergetics of COVID-19 immunopathology and the therapeutic potential of biophysical radiances","volume":"213","author":"Surazakov","year":"2020","journal-title":"J. Photochem. Photobiol. B."},{"key":"10.1016\/j.ymeth.2021.04.026_b1105","article-title":"Potential of laser-induced fluorescence-light detection and ranging for future stand-off virus surveillance","author":"Owoicho","year":"2020","journal-title":"Microb. Biotechnol."}],"container-title":["Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046202321001262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046202321001262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:42:07Z","timestamp":1760924527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046202321001262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":221,"alternative-id":["S1046202321001262"],"URL":"https:\/\/doi.org\/10.1016\/j.ymeth.2021.04.026","relation":{},"ISSN":["1046-2023"],"issn-type":[{"value":"1046-2023","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches for SARS-CoV-2 infection","name":"articletitle","label":"Article Title"},{"value":"Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymeth.2021.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}